Funding for this research was provided by:
national health and medical research council (APP1073772)
national breast cancer foundation (PS-17-055)
Received: 4 August 2021
Accepted: 3 January 2023
First Online: 22 February 2023
: The protocol for this clinical trial has been reviewed and approved on 19 June 2015 by the Northern Sydney Local Health District Human Research Ethics Committee (HREC). This HREC is constituted and operates in accordance with the National Health and Medical Research Council’s ‘National Statement on Ethical Conduct in Human Research’ and the CPMP/ICH Note for Guidance on Good Clinical Practice. All patients must provide written informed consent before being enrolled in the trial.
: Not applicable.
: ES, KM and PK are inventors on a patent filed for the Breathe Well technology. KM and PK are founders, shareholders and directors of Opus Medical Pty Ltd, a company advancing the Breathe Well audiovisual biofeedback device.